Semprus BioSciences Corp.
This article was originally published in Start Up
While implantable and interventional medical devices have greatly improved patient care, the materials of which these devices are made can cause unwelcome complications such as infections, blood clots and restenosis. Device coatings help to alleviate these problems, but current coating technologies are less than ideal. Semprus BioSciences aims to permanently prevent device-related complications by altering their surface architectures. The company's core technology is based on the permanent application of stable polymers and biological agents to the surfaces of medical devices to achieve desired properties. These highly biocompatible materials will mask the foreign surfaces of devices, which serve as an ideal breeding ground for bacteria or blood clots.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Approaches to Neuropathic Pain," features profiles of Aestus Therapeutics, Arcion Therapeutics and Spinifex Pharmaceuticals. Plus these Start-Ups Across Health Care: Centrose, Semprus BioSciences and Voyage Medical.
The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.